Sen. Richard J. Durbin

Combating International Islamophobia Act This bill establishes within the Department of State the Office to Monitor and Combat Islamophobia and addresses related issues. The office shall monitor and combat acts of Islamophobia and Islamophobic incitement in foreign countries. The bill establishes the position of Special Envoy for Monitoring and Combating Islamophobia, who shall head the office. The bill also requires certain existing annual reports to Congress about human rights and religious freedom in foreign countries to include information about Islamophobia, such as information about (1) acts of physical violence or harassment of Muslim people, (2) instances of propaganda in government and nongovernment media that attempt to justify or promote hatred or incite violence against Muslim people, and (3) actions taken by a country's government to respond to such acts. The office shall coordinate and assist in preparing these portions of the reports.

Kenneth P. Thompson Begin Again Act This bill expands eligibility for the expungement of records related to a first-time drug possession offense. Current law permits expungement for offenders who commit the offense before age 21. This bill permits expungement for offenders who commit the offense at any age.

This resolution expresses support for the people of South Sudan in their efforts to establish an independent, stable, democratic, and prosperous country.

Humane Cosmetics Act of 2021 This bill generally prohibits animal testing in the evaluation of cosmetic products, and it prohibits the sale or transport of cosmetics developed using animal testing, subject to civil penalties. These prohibitions begin one year after enactment. The bill specifies exceptions to these prohibitions, including if such animal testing (1) is conducted outside the United States to comply with a foreign regulatory authority; (2) is pursuant to a specified finding that there are no nonanimal alternatives to test the safety of a potentially dangerous cosmetic product or ingredient; (3) is of a product or ingredient for a drug or device subject to regulation by the Food and Drug Administration (FDA); or (4) is required for a noncosmetic purpose pursuant to a state, federal, or foreign regulatory authority. Further, no animal-testing evidence may be used to establish the safety of a cosmetic product or ingredient that is regulated by the FDA after the effective date of this bill, subject to limited exceptions.

Elementary and Secondary School Counseling Act This bill directs the Department of Education to award formula grants to state educational agencies and, through them, subgrants to local educational agencies to increase access to school-based, mental-health-services providers at high-need public elementary and secondary schools.

Preserve Access to Affordable Generics and Biosimilars Act This bill authorizes the Federal Trade Commission (FTC) to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement is presumed to have anticompetitive effects and is a violation of this bill if the filer of the generic drug or biosimilar application receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar. An agreement is exempted if the only consideration granted to the generic manufacturer is (1) the right to market and secure final approval for its product prior to the expiration of any statutory exclusivity, (2) a payment for reasonable litigation expenses, or (3) a covenant not to sue on any claim that the generic drug or biosimilar infringes a patent. An agreement is also exempt if the agreement's pro-competitive benefits outweigh the anticompetitive effects. When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing, or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains the complete agreement and any agreements related to that main agreement, including descriptions of any oral agreements or representations. The bill imposes penalties for violations of this bill, including the forfeiture of the 180-day marketing exclusivity period for a generic drug.

Maddy summaryThis is a ceremonial Senate resolution (SRES 470) commemorating the death of former U.S. Senator Bob Dole of Kansas. It formally expresses the Senate's sorrow, requests the Secretary of the Senate transmit a copy to Dole's family, and directs the Senate to adjourn as a mark of respect. The resolution has no policy or legal effect - it solely serves as a symbolic tribute to Dole's public service career. It does not affect any individuals or enact new laws.

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug. The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

Opioid Quota Openness, Transparency, and Awareness Act of 2021 or the Opioid QuOTA Act of 2021 This bill requires the Drug Enforcement Administration to make publicly available on its website certain information regarding opioid procurement quotas. The term opioid procurement quota means the maximum quantity of opioid analgesics that a registered manufacturer may procure.

This bill extends until May 8, 2038, the authority of the Department of the Interior to provide financial assistance to the Abraham Lincoln National Heritage Area in Illinois.